News | Radiopharmaceuticals and Tracers | January 30, 2019

ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial

CD8+ T Cell agent could be used for early prediction of therapeutic response in metastatic cancer patients

ImaginAb Enrolls First Patient in Phase II PET Agent Clinical Trial

January 30, 2019 - ImaginAb Inc. announced the enrollment of the first patient in the Phase II clinical trial of the company’s CD8+ T Cell imaging agent. The trial will enroll metastatic cancer patients and will study the correlation of imaging signals observed using ImaginAb’s CD8+ T cell ImmunoPET imaging agent, standard-of-care scans and immunohistochemistry analysis of CD8 in biopsied tissues. The trial will also measure changes in CD8+ T-cell distribution before and after immuno-oncology therapies. The study is, in part, financially supported by Boehringer Ingelheim and contributes to the aims of the strategic collaboration between ImaginAb and Boehringer Ingelheim to develop ImaginAb’s CD8+ T cell Immuno-PET imaging agent, IAB22M2C.

IAB22M2C is designed to be used with positron emission tomography (PET) scan technology to non-invasively measure CD8+ T cell tumor infiltrates in patients with cancer, including the identification of changes in CD8+ T cell tumor infiltrates induced by immuno-oncology treatments. This investigational approach has the potential to guide the development of immunomodulatory agents and combinations by assessing whether a patient’s immune system responds to such agents, thereby offering an early prediction of therapeutic response.

The Phase II trial follows on the heels of a recently completed Phase I study which, according to ImaginAb, showed an excellent safety profile and encouraging preliminary efficacy of the radiotracer.

For more information: www.imaginab.com

Related Content

Strategies to help guide nuclear radiology teams at various healthcare systems in 2021 and beyond
Feature | Nuclear Imaging | September 16, 2021 | By Staff of the American Society of Nuclear Cardiology (ASNC)
A year after COVID-19 turned the world upside do
Evaluation of therapeutic efficacy of drug candidates in preclinical oncology with positron emission tomography (PET)

Getty Images

Feature | PET Imaging | September 14, 2021 | By Todd Sasser, Ph.D.
Plan to attend RSNA21 at McCormick Place Chicago, Nov. 28 – Dec. 2, 2021

Getty Images

News | RSNA | September 13, 2021
September 13, 2021 — The Radiological Society of North America (RSNA) today announced highlights of the Technical Exh
Laws designed to help women with increased risk for missed breast cancer diagnoses may help catch the disease earlier, according to Penn State College of Medicine researchers.

Getty Images | AleksandarNakic

News | Breast Imaging | September 09, 2021
September 9, 2021 — Laws designed to help women with increased risk for...

Image of a STING protein, courtesy of UCLA Jonsson Comprehensive Cancer Center

News | PET Imaging | September 08, 2021
September 8, 2021 — A new study from scientists at the UCLA Jonsso...
62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

62-Year-Old Woman Who Underwent Hysterectomy for Uterine Cancer: Sagittal chest CT images demonstrate measurement of right (A) and left (B) lung length at hilar level from apex to diaphragmatic dome. Right lung length was 20.1 cm for reader 1 and 20.0 cm for reader 2; left lung length was 21.7 cm for reader 1 and 21.3 cm for reader 2. Patient did not require postoperative mechanical ventilation.

News | Computed Tomography (CT) | September 07, 2021
Neuroscientists at the Beckman Institute for Advanced Science and Technology carried out comparative studies to determine safe operating conditions for multiband EEG-fMRI imaging while maintaining acceptable data quality standards

A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Technology including Sepideh Sadaghiani, Maximillian Egan, Ryan Larsen, and Brad Sutton published a study to establish safe use of electroencephalography coupled with newly developed functional MRI sequences. Image courtesy of the Beckman Institute for Advanced Science and Technology.

News | Magnetic Resonance Imaging (MRI) | September 07, 2021
September 7, 2021 — A team of psychologists and neuroscientists at the Beckman Institute for Advanced Science and Tec
Gallium-68 from GalliaPharm is used for the preparation of diagnostic imaging drugs in Positron Emission Tomography (PET).
News | PET Imaging | September 03, 2021
September 3, 2021 — Eckert & Ziegler Radiopharma GmbH has successfully submitted an amendment to their Drug Maste